Theriva Biologics
TOVX
26 hedge funds and large institutions have $496K invested in Theriva Biologics in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
29% more capital invested
Capital invested by funds: $385K → $496K (+$110K)
18% more funds holding
Funds holding: 22 → 26 (+4)
0.03% more ownership
Funds ownership: 4.28% → 4.32% (+0.03%)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$87.1K |
| 2 |
Jane Street
New York
|
+$45.9K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$24.5K |
| 4 |
Renaissance Technologies
New York
|
+$18.9K |
| 5 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$10.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$49.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$48.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$46.3K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$25.3K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$12.1K |
TOVX Hedge Fund Activity: Q2 2026 in Review
26 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q2 2026, worth a combined $496K — up 29% from $385K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TOVX positions and 2 closed out — a net gain of 4 holders — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Capital Management, adding an estimated $87.1K. The largest seller was Virtu Financial, cutting an estimated $49.2K.
- 26 institutional investors held Theriva Biologics (TOVX) as of Q2 2026, up from 22 in Q1 2026.
- Funds reported $496K of Theriva Biologics stock for Q2 2026, up 29% quarter-over-quarter.
- 6 funds opened new Theriva Biologics positions in Q2 2026 and 2 closed out, a net change of +4 holders.
- The largest Theriva Biologics buyer in Q2 2026 was Vanguard Capital Management, an estimated $87.1K added.
- The largest Theriva Biologics seller in Q2 2026 was Virtu Financial, an estimated $49.2K sold.
Based on aggregated 13F filings for Q2 2026.